Particle.news
Download on the App Store
4 ARTICLES
·
2w ago

NHS Fast-Tracks Advanced Melanoma Patients for iSCIB1+ Cancer Vaccine Trial

The expanded Cancer Vaccine Launch Pad aims to revolutionize cancer care with personalized immunotherapy, targeting 10,000 patients by 2030.

Image
A dermatologist looking for signs of skin cancer. Melanoma is the fifth most common cancer in the UK

Overview

  • The NHS has launched a fast-track trial for the iSCIB1+ cancer vaccine, designed to enhance immune response in advanced melanoma patients.
  • The trial, part of the Cancer Vaccine Launch Pad (CVLP), expands the programme from bowel cancer to melanoma, reflecting rising skin cancer rates in the UK.
  • Seven NHS sites are initially participating, with patient referrals expected to begin next month, in collaboration with life-sciences company Scancell.
  • The CVLP aims to provide personalized cancer treatments to up to 10,000 patients in England by 2030, advancing precision medicine in public healthcare.
  • Key figures, including NHS cancer director Prof Peter Johnson and Prime Minister Keir Starmer, have endorsed the initiative as a transformative step in cancer care.